

Docket Number: 067074-0312419

PATENT APPLICATION

Client Reference: PCB/JM/P089100PUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

JOHN JENKINS

Group Art Unit:

Application No.: 10/511,001

Examiner:

Filed: October 12, 2004

Confirmation No.:

For: COMBINATION OF AN AGENT THAT ATTENUATES TOPOISOMERASE 1 ACTIVITY
AND AN AGENT THAT INHIBITS HEAT SHOCK PROTEIN 90 FOR USE IN
CHEMOTHERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants respectfully request the Examiner return an initialed copy of the enclosed Form PTO-1449 to Applicants with the next Office communication to indicate that the reference(s) has been considered, per MPEP § 609.

This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

The reference(s) was/were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

The references cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. According to the Notification of Acceptance in this file, copies of the references are already in the U.S. Patent Office file. Thus additional copies of the references are not attached.

Respectfully Submitted,



Richard H. Zaitlen
Registration Number 27248
Customer Number: 27496


Date: June 8, 2005
PILLSBURY WINTHROP SHAW PITTMAN LLP
Telephone: (213) 488-7100
Facsimile: (213) 629-1033
725 South Figueroa Street
Suite 2800
Los Angeles, CA 90017-5406

CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)


I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: ¹⁰June 8, 2005


Signature

LINDA E. BAKKE
(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(j). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,001
Filing Date	10/12/2004
First Named Inventor	JOHN JENKINS
Art Unit	
Examiner Name	
Attorney Docket Number	067074-0312419

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/J.L./	See Attachment 1		
/J.L./	C2	XIANG, YI, "The Anti-Proliferative Effect of Inhibitor of Telomerase on Cultured Retinal Pigment Epithelial Cells," Journal of Tongji Medical University, Haazhong University of Science and Technology, Vol. 20 (No. 4), p. 174-176, (2000).	
/J.L./	C3	BANERJI, UDAI ET AL., "The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future," The Institute of Cancer Research, Bentham Science Publishers Ltd., p. 385-390, (2003).	

Examiner Signature	/Jonathan Lau/	Date Considered	08/20/2008
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Information Disclosure Statement by Applicant (PTO/SB/08B);
Additional Other Prior Art - Non Patent Literature Documents

Attachment 1

- a. C1
- b. CARDENAS, MARIA E. ET AL., "Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System to Study Drug Action," Clinical Microbiology Reviews, American Society for Microbiology, Vol. 12 (No. 4), p. 1-56, (October 1999).
- c.